Tables of Findings for:

COMPETING COMMITMENTS in CLINICAL TRIALS

Charles W. Lidz PhD, Research Professor of Psychiatry Center for Mental Health Services Research, UMass Medical School

Paul S. Appelbaum M.D. Professor of Psychiatry, Columbia University College of Physicians and Surgeons and NY State Psychiatric Institute

> Steven Joffe M.D., M.P.H., Assistant Professor of Pediatrics Dana Farber Cancer Institute, Harvard University Medical School

Karen Albert M.A. Project Coordinator Center for Mental Health Services Research, UMass Medical School

Jill Rosenbaum B.A. Graduate Student Department of Psychology, University of Alabama-Tuscaloosa

Lorna Simon M.A. Biostatistician Center for Mental Health Services Research, UMass Medical School

Published in IRB: Ethics and Human Research, 31, 5, 2009

Characteristic	Number*	Percent	
Gender			
	501	79.90/	
Female	581	78.8%	
Male	156	21.2%	
Age			
<30	56	7.6%	
30-39	206	27.8%	
40-49	246	33.2%	
50-59	193	26.1%	
60+	39	5.3%	
Race/Ethnicity			
White	648	88.1%	
Black	21	2.9%	
Asian	45	6.1%	
Other	22	3.0%	
Training			
Physicians	147	19.8%	
Other Doctoral	23	3.1%	
Nursing	337	44.5%	
Other Masters	105	14.2%	
Others	129	17.8%	
# of CTs in last 2 years			
1 to 6	71	9.6%	
		9.6%	
7 to 10	140	18.9%	
11 to 15	183	24.7%	
16 to 20	127	17.1%	
21+	220	29.7%	

Table 1: Respondent Characteristics

*Numbers may not sum to 741 due to missing responses to individual questions

	Alw	vays	Frequ	ently	Occasion	nally	Ra	rely	Ne	ver
	MDs	Others	MDs	Others	MDs	Others	MDs	Others	MDs	Others
Participate in the	14	9	34	23	25	65	24	108	46	385
design of the trial N=733 p<.0001	9.8%	1.5%	23.8%	3.9%	17.5%	11.0%	16.8%	18.3%	32.2%	65.3%
Refer patients N=728	41	94	30	137	32	169	14	73	24	114
P<.05	29.1%	16.0%	21.3%	23.3%	22.7%	28.8%	9.9%	12.4%	17.0%	19.4%
Decide which study to	60	142	48	214	20	131	7	42	10	61
offer to patients N=735 p<.001	41.4%	24.1%	33.1%	36.3%	13.8%	22.2%	4.8%	7.1%	6.9%	10.3%
Participate in the	76	418	45	111	18	28	2	13	4	17
consent process N=732 P<.0001	52.4%	71.2%	31.0%	18.9%	12.4%	4.8%	1.4%	2.2%	2.8%	2.9%
Manage clinical care	77	295	40	126	15	76	5	18	7	76
of subjects N= 735 P<.05	53.55	49.9%	27.8%	21.3%	10.4%	12.9%	3.5%	3.1%	4.9%	12.9%
Collect data N=737	72	471	43	79	12	23	7	6	7	76
P<.0001	50.0%	79.4%	29.9%	13.3%	8.3%	3.9%	4.9%	1.0%	4.9%	12.9%
Analyze data N=729p<.0001	27	60	30	38	24	104	21	114	40	271
	19.0%	10.2%	21.1%	6.5%	16.9%	17.7%	14.8%	19.4%	28.2%	46.2%
Participate in drafting manuscripts N =732	21	16	27	24	23	52	24	92	47	406
P<.0001	14.8%	2.7%	19.0%	4.1%	16.2%	8.8%	16.9%	15.6%	33.1%	68.8%

Table 2: Study Roles Played by Survey Respondents

Question	Agree		Mostly Agree		Unc	ertain/	M	ostly	Disagree	
-					Ne	Neutral Disagree			-	
	M.D.s	Others	M.D.s	Others	M.D.s	Others	M.D.s	Others	M.D.s	Others
Research centers should	7	46	6	42	12	121	67	259	50	101
choose which trials to	4.9%	8.1%	4.2%	7.4%	8.5%	21.3%	41.2%	45.5%	35.2%	17.8%
participate in based on how										
much the trials contribute										
to science. N=711, p<.0001										
Researchers should only	27	88	39	86	17	100	39	176	22	134
participate in trials that are	18.8%	15.1%	27.1%	14.7%	11.8%	17.1%	27.1%	30.1%	15.3%	23.0%
likely to help the subjects										
who take part.										
N =728, p<.005										
Even if patients are	14	39	23	64	18	74	46	160	44	242
technically eligible for a	9.6%	6.7%	15.9%	11.1%	12.4%	12.8%	31.7%	27.6%	30.3%	41.8%
trail, they should only be										
recruited if being in the										
trial will be in their best										
medical interests. N=719,										
n.s.	• •	101								
Patients who are not doing	28	104	25	83	31	161	44	171	16	56
well with standard care	19.4%	18.1%	17.4%	14.4%	21.5%	28.0%	30.6%	29.7%	11.1%	9.7%
should be recruited most										
actively so that being in the										
trial can help them. N=719,										
n.s.	24	97	24	102	33	1.40	21	157	24	88
When several subjects at a site do considerably worse		86	24	102		140	31	157	34	
than would be expected in	16.4%	15.0%	16.4%	17.8%	22.6%	24.4%	21.2%	27.4%	23.4%	15.4%
ordinary care, that site										
should stop recruiting for										
that study. $N = 719$, n.s.										

Table 3: Attitudes toward Clinical Trials

Researchers should deviate	61	254	28	112	18	89	22	77	14	35
from the protocol if it	42.7%	44.8%	19.6%	19.6%	12.6%	15.7%	15.4%	13.6%	9.8%	6.2%
would improve the										
subject's medical care.										
N=710, n.s.										
The protocol should be	83	345	38	135	6	31	12	53	6	16
used as a guideline rather	57.2%	59.5%	26.2%	23.3%	4.1%	5.3%	8.3%	9.1%	4.1%	2.8%
than something to be										
strictly followed under all										
circumstances. N=725, n.s.										
It is okay to ignore minor	97	435	22	90	15	29	9	17	2	5
entry criteria if a patient	66.9%	75.7%	15.2%	15.5%	10.3%	5.0%	6.2%	2.9%	1.4%	0.9%
will benefit from being in										
the trial. N=719, p<.05										

Table 4: Clinical Behavior in Clinical Trials"How many times in the past two years...."

Question	0	1-2	3-5	6-10	11-15	16+	DK/N A
Have you had a patient who was eligible for a clinical trial, but being in the trial seemed <i>not</i> to be in the patient's best medical interests? N=671	15.7%	23.7%	25.3%	11.8%	2.8%	6.3%	14.5%
Was the trial not offered to the patient? $N = 665$	19.4%	23.9%	15.5%	7.7%	3.0%	4.4%	26.2%
Have you had a patient who was <i>not</i> technically eligible for a clinical trial, but being in the trial seemed to be in the patient's best medical	19.3%	17.2%	17.7%	15.9%	4.8%	13.0%	12.0%

interests? N=667							
Was the trial offered to the patient? N=660	62.4%	15.0%	3.8%	1.4%	1.1%	0.2%	16.2%
Was a medication restricted by protocol, but giving the medication seemed to be in the subject's best medical interests? N=670	26.1%	16.4%	15.8%	10.3%	3.0%	6.9%	21.5%
Was the medication given? N = 664	44.7%	17.8%	5.0%	2.9%	1.5%	0.9%	27.3%
When adjusting the dose of the medication seemed to be in the subject's best medical interests, but making the adjustment was not permitted by the protocol? N= 670	33.7%	17.2%	16.0%	7.3%	2.4%	5.1%	18.4%
Was the dose of the study medication adjusted? N=661	59.3%	9.6%	3.8%	1.4%	1.1%	0.2%	(24.8 %
When breaking a blind without reporting it seemed to be in the patient's best medical interests? N=672	75.6%	8.2%	1.9%	0.3%	0.2%	0.6%	13.2%
Have you decided to break the blind without reporting it? N=657	76.0%	0.9%	0.2%				23.0%
Have you had a subject who met termination criteria, but remaining in the trial seemed to be in the subject's best medical interests? N = 668	50.0%	18.6%	9.9%	4.0%	1.1%	2.7%	13.8%
Was the subject kept in trial? N=655	69.0%	6.7%	1.7%	0.2%	0.2%	0.2%	22.1%